

## Supplementary Materials

**Table S1.** Associations between placebo response and baseline characteristics.

	<i>p</i> Value *	Mean Difference	95% Confidence Interval of the Difference	
			Lower	Upper
Sex	0.18	N/A	N/A	N/A
Age	0.71	−0.39	−2.5	1.7
SRS T score	0.75	0.73	−3.8	5.2
Total SCQ score	0.32	1.6	−1.6	4.9
ADOS comparison score	0.65	0.18	−0.62	0.98
VABS composite score	0.77	−1.2	−9.0	6.4
CARS total score	0.5	1.5	−2.9	5.8

\* The categorical parameter sex was assessed using the Fisher's Exact Test. All the other parameters are continuous and were assessed using the two-sample *t*-test. ADOS-2: Autism Diagnostic Observation Schedule; CARS: Childhood Autism Rating Scale; SCQ: Social Communication Questionnaire score; SRS: Social Responsiveness Scale; VABS: Vineland Adaptive Behavior Scale.

**Table S2.** Associations between placebo response and symptom severity at baseline.

	<i>p</i> Value *	Mean Difference	95% Confidence Interval of the Difference	
			Lower	Upper
CGI-S	0.68	−0.1	−0.4	0.3
HSQ-ASD	0.25	−0.5	−1.3	0.35
SRS	0.84	1.6	−14.2	17.3
APSI	0.49	−2.0	−7.7	3.7

\* Two-sample *t*-test. APSI: Autism Parenting Stress Index; CGI-S: Clinical Global Impression-Severity (with disruptive behavior anchor points); HSQ-ASD: Home Situations Questionnaire-ASD; SRS: Social Responsiveness Scale.

**Table S3.** STROBE Statement—checklist of items that should be included in reports of observational studies.

	Item No.	Recommendation	Page No.	Relevant Text from Manuscript
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1	This retrospective study....
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found		Entire abstract
<b>Introduction</b>				
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	1,2	
Objectives	3	State specific objectives, including any prespecified hypotheses	2	
<b>Methods</b>				
Study design	4	Present key elements of study design early in the paper	3	
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	3,4	
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	3,4	
		<i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls		
		<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants		
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed		
Variables	7	<i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	3,4,5	
		Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable		
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	3–5	
Bias	9	Describe any efforts to address potential sources of bias	3–5	
Study size	10	Explain how the study size was arrived at	3–6	
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7	
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7	
		(b) Describe any methods used to examine subgroups and interactions	7	

		(c) Explain how missing data were addressed	NA
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed	
		<i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	NA
		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	NA
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	NA
		(b) Give reasons for non-participation at each stage	NA
		(c) Consider use of a flow diagram	NA
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Table 1
		(b) Indicate number of participants with missing data for each variable of interest	Table 1
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	Figure 1
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	NA
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	8
		(b) Report category boundaries when continuous variables were categorized	NA
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	NA
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	9–11
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	10
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	9–11
Generalisability	21	Discuss the generalisability (external validity) of the study results	9–11
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	11

\* Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies. Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).